8) that were uniquely enriched in visit 3 included: (1) ksgA , strA and strB for aminoglycosides, (2) bla CARB-4 , bla CMY-1 , bla CMY-2 , bla CTX-M-1 , bla CTX-M-12 , bla DHA-1 , bla OXA-1 , bla SHV-1 , bla SHV-37 , bla SHV-3 , bla TEM-1A and bla TEM-1B , for beta-lactams, and (3) tetA , tetB , tetC , tetK and tetL for tetracycline
Set expectations accordingly during consultation and document outcomes objectively
Analytical procedures should be fit for their stated purpose, and reported results should identify the analytical method, result, and acceptance criterion where applicable
G., Cipri, C
You can check if your specific insurance plan requires that your healthcare provider submit a prior authorization for Wegovy by reviewing your plans drug formulary